HK1124622A1 - Human monoclonal antibodies to fucosyl-gm1 and methods for using anti- fucosyl-gm1 - Google Patents
Human monoclonal antibodies to fucosyl-gm1 and methods for using anti- fucosyl-gm1Info
- Publication number
- HK1124622A1 HK1124622A1 HK09101904A HK09101904A HK1124622A1 HK 1124622 A1 HK1124622 A1 HK 1124622A1 HK 09101904 A HK09101904 A HK 09101904A HK 09101904 A HK09101904 A HK 09101904A HK 1124622 A1 HK1124622 A1 HK 1124622A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- fucosyl
- methods
- monoclonal antibodies
- human monoclonal
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74891505P | 2005-12-08 | 2005-12-08 | |
PCT/US2006/061817 WO2007067992A2 (fr) | 2005-12-08 | 2006-12-08 | Anticorps monoclonaux humains se liant au fucosyl-gm1, et procedes d'utilisation de l'anti-fucosyl-gm1 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1124622A1 true HK1124622A1 (en) | 2009-07-17 |
Family
ID=38123661
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09101904A HK1124622A1 (en) | 2005-12-08 | 2009-02-27 | Human monoclonal antibodies to fucosyl-gm1 and methods for using anti- fucosyl-gm1 |
HK13112220.2A HK1185085A1 (zh) | 2005-12-08 | 2013-10-30 | 抗岩藻糖基- 的人單克隆抗體及使用抗岩藻糖基- 抗體的方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK13112220.2A HK1185085A1 (zh) | 2005-12-08 | 2013-10-30 | 抗岩藻糖基- 的人單克隆抗體及使用抗岩藻糖基- 抗體的方法 |
Country Status (22)
Country | Link |
---|---|
US (6) | US8383118B2 (fr) |
EP (1) | EP1960434B1 (fr) |
JP (2) | JP5512128B2 (fr) |
KR (1) | KR101446510B1 (fr) |
CN (2) | CN101356195B (fr) |
AU (1) | AU2006321554B2 (fr) |
BR (1) | BRPI0620553A2 (fr) |
CA (1) | CA2638902C (fr) |
DK (1) | DK1960434T3 (fr) |
EA (1) | EA017491B1 (fr) |
ES (1) | ES2390476T3 (fr) |
HK (2) | HK1124622A1 (fr) |
HR (1) | HRP20120701T1 (fr) |
IL (2) | IL191610A (fr) |
NO (1) | NO20083062L (fr) |
NZ (1) | NZ568551A (fr) |
PL (1) | PL1960434T3 (fr) |
PT (1) | PT1960434E (fr) |
SG (1) | SG174783A1 (fr) |
SI (1) | SI1960434T1 (fr) |
WO (1) | WO2007067992A2 (fr) |
ZA (1) | ZA200804971B (fr) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0620553A2 (pt) | 2005-12-08 | 2011-11-16 | Medarex Inc | anticorpo monoclonal humano isolado ou uma porção ligante ao antìgeno do mesmo, composição, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para preparar um anticorpo anti-fucosil-gm1 e método para tratar ou prevenir uma doença definida pelo crescimento de células tumorais expressando fucosil-gm1 |
US8188235B2 (en) | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
EP3079431B1 (fr) * | 2013-12-05 | 2019-06-19 | LG Electronics Inc. | Procédé et dispositif mtc d'exécution d'une procédure d'accès aléatoire pour l'amélioration de la couverture |
ES2939760T3 (es) | 2014-03-15 | 2023-04-26 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico para antígenos |
WO2016014530A1 (fr) | 2014-07-21 | 2016-01-28 | Novartis Ag | Combinaisons de faibles doses renforçant l'immunité d'inhibiteurs de mtor et car |
WO2016049256A1 (fr) | 2014-09-25 | 2016-03-31 | Bristol-Myers Squibb Company | Traitement du cancer du poumon au moyen d'un anticorps anti-fucosyl-gm1 |
ES2783624T3 (es) | 2015-01-14 | 2020-09-17 | Bristol Myers Squibb Co | Dímeros de benzodiacepina, conjugados de los mismos y métodos de preparación y uso |
ES2747386T3 (es) | 2015-01-14 | 2020-03-10 | Bristol Myers Squibb Co | Dímeros de benzodiacepina unidos por heteroarileno, conjugados de los mismos y métodos de preparación y uso |
US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
EP3286211A1 (fr) | 2015-04-23 | 2018-02-28 | Novartis AG | Traitement du cancer à l'aide de protéine récepteur antigénique chimérique et un inhibiteur de protéine kinase |
US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
CN106550478B (zh) * | 2015-09-22 | 2020-08-04 | 中兴通讯股份有限公司 | 一种多用户传输网络分配矢量设置方法和装置 |
JP2018536404A (ja) | 2015-11-09 | 2018-12-13 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Cho細胞において産生したポリペプチドの品質特性を操作する方法 |
CN116334143A (zh) | 2015-11-23 | 2023-06-27 | 诺华股份有限公司 | 优化的慢病毒转移载体及其用途 |
KR20180089433A (ko) | 2015-12-21 | 2018-08-08 | 브리스톨-마이어스 스큅 컴퍼니 | 부위-특이적 접합을 위한 변이체 항체 |
JP2019500394A (ja) | 2015-12-30 | 2019-01-10 | ノバルティス アーゲー | 有効性が増強された免疫エフェクター細胞治療 |
AU2017209083A1 (en) | 2016-01-22 | 2018-07-12 | Adimab, Llc | Anti-coagulation factor XI antibodies |
WO2017165683A1 (fr) | 2016-03-23 | 2017-09-28 | Novartis Ag | Mini-corps sécrétés par des cellules et leurs usages |
US11104739B2 (en) * | 2016-04-14 | 2021-08-31 | Bristol-Myers Squibb Company | Combination therapy using an anti-fucosyl-GM1 antibody and an anti-CD137 antibody |
WO2017210335A1 (fr) | 2016-06-01 | 2017-12-07 | Bristol-Myers Squibb Company | Méthodes d'imagerie faisant intervenir des substances biologiques radiomarquées au 18f |
CR20180583A (es) | 2016-06-14 | 2019-07-02 | Merck Sharp & Dohme | Anticuerpos antifactor de la coagulación xi |
EP3500574B1 (fr) | 2016-08-19 | 2021-11-24 | Bristol-Myers Squibb Company | Composés de seco-cyclopropapyrroloindole, conjugués anticorps-médicament de ceux-ci, et procédés de fabrication et d'utilisation |
US10398783B2 (en) | 2016-10-20 | 2019-09-03 | Bristol-Myers Squibb Company | Antiproliferative compounds and conjugates made therefrom |
WO2018111340A1 (fr) | 2016-12-16 | 2018-06-21 | Novartis Ag | Procédés de détermination de la puissance et de la fonction proliférative de lymphocytes t à récepteur antigénique chimérique (car) |
EP3574005B1 (fr) | 2017-01-26 | 2021-12-15 | Novartis AG | Compositions de cd28 et procédés pour une thérapie à base de récepteur antigénique chimérique |
CN110582509A (zh) | 2017-01-31 | 2019-12-17 | 诺华股份有限公司 | 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症 |
WO2018229715A1 (fr) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprenant des anticorps anti-cd32b et procédés d'utilisation correspondants |
CN107688093B (zh) * | 2017-08-25 | 2020-04-07 | 李红俊 | 肺癌检测试纸条、试剂盒及其使用方法 |
BR112020004489A2 (pt) | 2017-09-07 | 2020-09-08 | Dragonfly Therapeutics, Inc. | proteínas de ligação ao nkg2d, cd16 e um antígeno associado a tumor |
EP3700926A1 (fr) | 2017-10-25 | 2020-09-02 | Novartis AG | Procédés de conception de cellules d'expression de récepteur antigénique chimérique |
EP3700933A1 (fr) | 2017-10-25 | 2020-09-02 | Novartis AG | Anticorps ciblant cd32b et leurs procédés d'utilisation |
EP3784351A1 (fr) | 2018-04-27 | 2021-03-03 | Novartis AG | Thérapies reposant sur des cellules car-t présentant une efficacité améliorée |
WO2019213282A1 (fr) | 2018-05-01 | 2019-11-07 | Novartis Ag | Biomarqueurs pour évaluer des cellules car-t pour prédire un résultat clinique |
US20210213063A1 (en) | 2018-05-25 | 2021-07-15 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
IL312163A (en) | 2018-05-29 | 2024-06-01 | Bristol Myers Squibb Co | Modified atom groups that sacrifice themselves for use in prodrugs and conjugates and methods of use and preparation |
EP3802825A1 (fr) | 2018-06-08 | 2021-04-14 | Intellia Therapeutics, Inc. | Compositions et procédés d'immuno-oncologie |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
JP7389803B2 (ja) | 2018-11-30 | 2023-11-30 | ブリストル-マイヤーズ スクイブ カンパニー | グルタミンを含有する軽鎖c末端に伸長部分を含む抗体およびそのコンジュゲートならびにその方法および用途 |
US20220031860A1 (en) | 2018-12-12 | 2022-02-03 | Bristol-Myers Squibb Company | Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses |
US20240245670A1 (en) | 2018-12-20 | 2024-07-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
BR112021015672A2 (pt) | 2019-02-15 | 2021-10-05 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos |
EP3924054A1 (fr) | 2019-02-15 | 2021-12-22 | Novartis AG | Dérivés de 3-(1-oxo-5-(pipéridin-4-yl)isoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations |
GB201912657D0 (en) | 2019-09-03 | 2019-10-16 | Scancell Ltd | Binding members |
WO2021123902A1 (fr) | 2019-12-20 | 2021-06-24 | Novartis Ag | Combinaison d'anticorps anti-tim-3 mbg453 et d'anticorps anti-tgf-bêta nis793, avec ou sans décitabine ou l'anticorps anti pd-1 spartalizumab, pour le traitement de la myélofibrose et du syndrome myélodysplasique |
EP4165169A1 (fr) | 2020-06-11 | 2023-04-19 | Novartis AG | Inhibiteurs de zbtb32 et leurs utilisations |
MX2022015852A (es) | 2020-06-23 | 2023-01-24 | Novartis Ag | Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona. |
US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
EP4274850A1 (fr) | 2021-01-08 | 2023-11-15 | Bristol-Myers Squibb Company | Polythérapie utilisant un anticorps anti-fucosyl-gm1 |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
AU2022267891A1 (en) | 2021-04-27 | 2023-11-09 | Novartis Ag | Viral vector production system |
CN115261315A (zh) * | 2022-03-24 | 2022-11-01 | 宁夏医科大学总医院 | 一种筛选并富集神经节苷脂抗原特异性b细胞方法和装置 |
WO2023214325A1 (fr) | 2022-05-05 | 2023-11-09 | Novartis Ag | Dérivés de pyrazolopyrimidine et leurs utilisations en tant qu'inhibiteurs de tet2 |
WO2024089639A1 (fr) | 2022-10-26 | 2024-05-02 | Novartis Ag | Formulations lentivirales |
CN115850496B (zh) * | 2022-11-28 | 2023-05-23 | 山东纳睿博恩生物医药科技有限公司 | Fuca1特异性抗体及其应用 |
Family Cites Families (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4867973A (en) * | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
EP0154316B1 (fr) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Lymphokine chimiquement modifiée et son procédé de préparation |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4954617A (en) | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
WO1988009344A1 (fr) | 1987-05-21 | 1988-12-01 | Creative Biomolecules, Inc. | Proteines mutifonctionnelles a cible predeterminee |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
DE68925966T2 (de) | 1988-12-22 | 1996-08-29 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
ATE356869T1 (de) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
WO1994025585A1 (fr) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Animaux transgeniques capables de produire des anticorps heterologues |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DE69233745D1 (de) | 1991-12-02 | 2008-10-23 | Cambridge Antibody Tech | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
EP0746609A4 (fr) | 1991-12-17 | 1997-12-17 | Genpharm Int | Animaux transgeniques non humains capables de produire des anticorps heterologues |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
EP0640094A1 (fr) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Production recombinante de domaines semblables a l'immunoglobuline dans des cellules procaryotes |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
EP0714409A1 (fr) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Anticorps |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
EP1709970A1 (fr) * | 1995-04-27 | 2006-10-11 | Abgenix, Inc. | Anticorps humains contre le EGFR, produit par des souris transgéniques |
WO1997012862A1 (fr) | 1995-10-03 | 1997-04-10 | The Scripps Research Institute | Analogues de cbi de cc-1065 et des duocarmycines |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
DE69833755T2 (de) | 1997-05-21 | 2006-12-28 | Biovation Ltd. | Verfahren zur herstellung von nicht-immunogenen proteinen |
DE69825048D1 (de) | 1997-05-22 | 2004-08-19 | Scripps Research Inst | Analoga von duocarmycin and cc-1065 |
WO1999015201A1 (fr) | 1997-09-25 | 1999-04-01 | Sloan-Kettering Institute For Cancer Research | Vaccin a conjugue fucosyle gm1-klh contre le cancer du poumon a petites cellules |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
PT2180007E (pt) | 1998-04-20 | 2013-11-25 | Roche Glycart Ag | Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
CA2359067C (fr) | 1999-01-15 | 2017-03-14 | Genentech, Inc. | Variants polypeptidiques ayant une fonction effectrice alteree |
EP2270147B2 (fr) | 1999-04-09 | 2020-07-22 | Kyowa Kirin Co., Ltd. | Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle |
NZ517372A (en) | 1999-07-29 | 2004-04-30 | Medarex Inc | Human monoclonal antibodies to HER2/neu |
US7854934B2 (en) | 1999-08-20 | 2010-12-21 | Sloan-Kettering Institute For Cancer Research | Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof |
ES2267559T3 (es) | 1999-08-20 | 2007-03-16 | Sloan-Kettering Institute For Cancer Research | Glicoconjugados, glicoamino, acidos sus intermediarios y el uso de los mismos. |
US7824687B2 (en) | 1999-08-20 | 2010-11-02 | Sloan-Kettering Institute For Cancer Research | Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof |
NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
EP1350085B1 (fr) * | 2000-11-02 | 2008-12-31 | ImmunoCellular Therapeutics, Ltd. | Anticorps monoclonaux et antigenes de surface pour la detection et le traitement du cancer a petites cellules (sclc) |
PT1354034E (pt) | 2000-11-30 | 2008-02-28 | Medarex Inc | Roedores transgénicos transcromossómicos para produção de anticorpos humanos |
EP1421203A4 (fr) | 2001-05-17 | 2005-06-01 | Diversa Corp | Nouvelles molecules de liaison a un antigene destinees a des applications therapeutiques, diagnostiques, prophylactiques, enzymatiques, industrielles et agricoles et procedes de generation et de criblage de telles molecules |
WO2002096910A1 (fr) | 2001-05-31 | 2002-12-05 | Medarex, Inc. | Cytotoxines, promedicaments, lieurs et stabilisateurs utiles pour ceux-ci |
WO2002100353A2 (fr) | 2001-06-11 | 2002-12-19 | Medarex, Inc. | Composes pour promedicaments actives cd10 |
CA2459308A1 (fr) | 2001-09-07 | 2003-03-20 | Dale L. Boger | Analogues cbi de cc-1065 et des duocarmycines |
HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
BR0309145A (pt) | 2002-04-09 | 2005-02-01 | Kyowa Hakko Kogyo Kk | Células das quais o genoma é modificado |
US8110664B2 (en) * | 2002-11-29 | 2012-02-07 | Rsr Limited | Binding partners for the thyrotropin receptor and uses thereof |
US20060035267A1 (en) | 2003-04-09 | 2006-02-16 | Livingston Philip O | Optimal polyvalent vaccine for cancer |
CA2521812A1 (fr) | 2003-04-09 | 2004-10-28 | Sloan-Kettering Institute For Cancer Research | Vaccin polyvalent optimal contre le cancer |
BRPI0620553A2 (pt) | 2005-12-08 | 2011-11-16 | Medarex Inc | anticorpo monoclonal humano isolado ou uma porção ligante ao antìgeno do mesmo, composição, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para preparar um anticorpo anti-fucosil-gm1 e método para tratar ou prevenir uma doença definida pelo crescimento de células tumorais expressando fucosil-gm1 |
-
2006
- 2006-12-08 BR BRPI0620553-4A patent/BRPI0620553A2/pt not_active Application Discontinuation
- 2006-12-08 EA EA200870021A patent/EA017491B1/ru not_active IP Right Cessation
- 2006-12-08 CA CA 2638902 patent/CA2638902C/fr active Active
- 2006-12-08 CN CN2006800507255A patent/CN101356195B/zh active Active
- 2006-12-08 SG SG2011064292A patent/SG174783A1/en unknown
- 2006-12-08 JP JP2008544669A patent/JP5512128B2/ja active Active
- 2006-12-08 CN CN201310078938.0A patent/CN103204931B/zh active Active
- 2006-12-08 AU AU2006321554A patent/AU2006321554B2/en active Active
- 2006-12-08 DK DK06840172T patent/DK1960434T3/da active
- 2006-12-08 EP EP06840172A patent/EP1960434B1/fr active Active
- 2006-12-08 PL PL06840172T patent/PL1960434T3/pl unknown
- 2006-12-08 ES ES06840172T patent/ES2390476T3/es active Active
- 2006-12-08 NZ NZ568551A patent/NZ568551A/en unknown
- 2006-12-08 PT PT06840172T patent/PT1960434E/pt unknown
- 2006-12-08 KR KR20087015517A patent/KR101446510B1/ko active IP Right Grant
- 2006-12-08 SI SI200631438T patent/SI1960434T1/sl unknown
- 2006-12-08 WO PCT/US2006/061817 patent/WO2007067992A2/fr active Application Filing
- 2006-12-08 US US12/095,557 patent/US8383118B2/en active Active
-
2008
- 2008-05-21 IL IL191610A patent/IL191610A/en active IP Right Grant
- 2008-06-06 ZA ZA200804971A patent/ZA200804971B/xx unknown
- 2008-07-08 NO NO20083062A patent/NO20083062L/no not_active Application Discontinuation
-
2009
- 2009-02-27 HK HK09101904A patent/HK1124622A1/xx unknown
-
2012
- 2012-09-04 HR HRP20120701TT patent/HRP20120701T1/hr unknown
-
2013
- 2013-01-22 US US13/746,762 patent/US9138475B2/en active Active
- 2013-10-30 HK HK13112220.2A patent/HK1185085A1/zh unknown
-
2014
- 2014-02-19 JP JP2014029047A patent/JP5897051B2/ja active Active
- 2014-02-26 IL IL231169A patent/IL231169A0/en unknown
-
2015
- 2015-08-13 US US14/825,661 patent/US9631025B2/en active Active
-
2017
- 2017-03-17 US US15/462,758 patent/US20170190785A1/en not_active Abandoned
-
2019
- 2019-05-17 US US16/415,829 patent/US20190315881A1/en not_active Abandoned
-
2022
- 2022-08-05 US US17/817,751 patent/US20220403046A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL231169A0 (en) | Human monoclonal antibodies to fucosil - 1gm and methods of using antibodies against fucosil - 1gm | |
IL191340A (en) | Monoclonal antibodies against e8o | |
HK1219488A1 (zh) | 針對類活化素受體激酶- 之人類單株抗體 | |
HRP20181616T1 (hr) | Potpuno ljudska anti-vap-1 monoklonska antitijela | |
IL189788A0 (en) | Human monoclonal antibodies to cd70 | |
IL179672A (en) | Monoclonal antibodies against 3 cd human | |
IL184733A0 (en) | Human monoclonal antibodies to prostate specific membrane | |
IL192129A0 (en) | Anti-mn antibodies and methods of using same | |
ZA200710496B (en) | Antibodies directed to CD20 and used thereof | |
IL200610A0 (en) | Human monoclonal anti-ip-10 antibodies and uses thereof | |
ZA200804868B (en) | Anti-OX40L antibodies and methods using same | |
IL198729A0 (en) | Human monoclonal antibodies to btla and methods of use | |
EP1915177A4 (fr) | Anticorps d'alpha-synucléine et techniques associées | |
ZA200802641B (en) | Human monoclonal antibodies to CD70 | |
EP1947178A4 (fr) | Anticorps humain monoclonal se liant au gm-csf humain et site de liaison à l'antigène de cet anticorps | |
IL192419A0 (en) | Anti-ephb4 antibodies and methods using same | |
IL231891A (en) | Anti-ephrinb2 antibodies and methods for their use | |
EP2185718A4 (fr) | Anticorps monoclonaux humains et procédés de production | |
ZA200806053B (en) | Anti-EphB4 antibodies and methods using same | |
ZA200804254B (en) | Human monoclonal antibodies to O8E | |
GB0506945D0 (en) | Human antibodies | |
GB0503190D0 (en) | Human antibodies | |
GB0502201D0 (en) | Human antibodies |